| Backgroud and objective: With the economic development and the continuous improvement of people’s living standards and the improvement of medical conditions,people are paying more and more attention to health.At present,the incidence of prostate cancer in the Chinese population is gradually rising,increasing the medical burden on the society and the people.Research on the mechanism of the occurrence and development of prostate cancer is the current research hotspot.Most patients with prostate cancer will progress to castration-resistant prostate cancer in advanced stages.A large number of studies have shown that prostate cancer progression is closely related to long-chain non-coding RNA(lnc RNA)PCAT-1.This study aims to explore the relationship between lnc RNA PCAT-1 and the clinical progress and prognosis of prostate cancer.A large number of studies have confirmed the important role of lnc RNA in the occurrence and development of prostate cancer.PCAT-1 is a type of lnc RNA.The researchers found that it is located in the region of chromosome 8q24.It is highly expressed in prostate cancer tissues,which can promote the proliferation,invasion and Malignant phenotypes such as spread,however,the relationship between PCAT-1 and the therapeutic effect of patients with prostate cancer is still unclear.In this study,the expression of PCAT-1 in the urine of prostate cancer patients was compared with that of prostate cancer patients.The relationship between serum PSA response rate,so as to evaluate the value of PCAT-1 as a new prostate cancer tissue marker in predicting the clinical progress and treatment of prostate.Methods: Collect clinical data of 93 patients with prostate cancer,including age,medication history,surgical history,pathology,and imaging data,and collect PSA test records of patients during medication.Collect the urine samples of the patients,extract the lnc RNA of the urine samples,detect the expression level of PCAT-1 by RT-PCR technology,and obtain the expression distribution map of PCAT-1 of patients in different periods after data processing,and analyze the results of PCAT-1 To compare whether there are statistical differences between the groups.Introduce factors such as before and after surgery,effectiveness of chemotherapy and effectiveness of taking abiraterone,compare their correlation with PCAT-1,and analyze whether it is statistically significant.Results: Urine PCAT-1 expression in CRPC group((?)=0.75,S=0.46)was significantly higher than that in HSPC group((?)=0.45,S=0.29),P<0.05 difference was statistically significant;CRPC-R group The expression of PCAT-1 in patients’ urine((?)=2.66,S=0.79)was significantly higher than that in CRPC group((?)=0.75,S=0.46),P<0.05,the difference was statistically significant;Urine PCAT-1 expression in chemotherapy patients((?)=3.10,S=0.54)was significantly higher than that in chemotherapy patients((?)=1.98,S=0.64),P<0.05,the difference was statistically significant;CRPC group was non-operative The expression of PCAT-1 in patients’ urine((?)=1.12,S=0.29)was significantly higher than that in surgical patients((?)=0.70,S=0.23),P<0.05,the difference was statistically significant..Conclusion: There is a certain correlation between the expression of PCAT-1 in urine of patients with prostate cancer and the patient’s disease progression,the effect of applying abiraterone,surgery and chemotherapy.The progression of the disease to the CRPC stage,Abiraterone resistance,and the absence of surgery and chemotherapy in patients with urine significantly increased the expression of PCAT-1.In the future,a more indepth study of Lnc RNA PCAT-1 will help more accurate prediction Prostate cancer patients’ disease progression and treatment prognosis. |
PDF Full Text Request